This round is no longer accepting investments, but hundreds just like it are live now.



The Next Generation of Food Allergy Testing

Allergenis provides the next generation of food allergy testing using cutting-edge systems biology and data analytics to accurately determine allergic status, tolerance levels, and reaction severity for a more informed quality of life when living with a diagnosis of food allergy. Additionally, Allergenis is the first food allergy test that can be initiated by a caregiver and/or individual via a partner telemedicine channel, all while receiving the necessary medical support from an allergist with expertise in managing food allergies. We currently provide peanut allergic status and threshold testing in 49 states, and Washington DC, with milk allergy testing launching later this year, and egg allergy testing in 2024.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$547,923.66 Raised


AllerGenis' patent-protected food allergy diagnostic platform offers 93% accuracy, the highest rate for peanut allergy diagnosis compared to 60% accuracy of current blood tests.** AllerGenis offers an in-market suite of peanut allergy tests and is in the advanced stages of development for additional food allergens.

AllerGenis is targeting the food allergy market with a current global valuation of $39B, expected to grow to $66B by the end of 2033.* The Company has partnered with multiple global therapeutic companies generating revenue. It offers its tests through food allergist practices, including the largest allergy clinics in the U.S., as well as directly to consumers via a tele-medicine platform.

AllerGenis has previously raised $19 million, and its expert team of senior leaders have successfully developed and commercialized many diagnostic products currently in use as well as leading meaningful corporate exits. AllerGenis is a Mount Sinai Innovation Partner (MSIP) company.

*Information from Future Market Insights (Source)

**Information based on an internal analysis of the total amino acids targeted by other tests, data on file as well as Wiley Online Library (Source)

The Pitch

Helping People with Food Allergies Live Safer, Healthier Lives

Over 32 million Americans have food allergies, including 1 in every 13 children or approximately 2 in every classroom (Source). As many as 60% are over-diagnosed with current blood and skin testing, causing a mental, emotional, and financial toll on individuals, caregivers, and their families (Source | Source). The gold standard in diagnosing food allergies is an oral food challenge (OFC) which is anxiety-inducing, time and resource-intensive, may incur a risk of anaphylactic reactions, and is not widely available in clinical practice (Source). The OFC is also often required by therapeutic products during clinical trials which can inhibit trial enrollment and slow time-to-market for treatment solutions.

Individuals need a comprehensive road map to understand if they are allergic, how allergic they are, what their threshold levels are, and whether they are at increased risk of experiencing a life-threatening reaction. The Allergenis diagnostic offers a safe, easy-to-access, alternative to an OFC with up to 93% accuracy, far superior to currently available blood or skin tests, that helps individuals get clarity on these questions (Source). 

Working with Hugh A. Sampson, M.D., the world's leading expert in the food allergy field at the Jaffe Food Allergy Institute at Mount Sinai and, who has devoted over 20 years to the development of the epitope (Source) based technology, Allergenis has an in-market, clinically available assay for peanuts, with multiple allergens (milk, egg, wheat, and tree nuts) in the pipeline. With these additional allergens available, Allergenis addresses 85% of pediatric food allergies in the United States. Finally, Allergenis is collaborating with 6 of more than 30 therapeutic companies, with meaningful, ongoing dialog with 10 others, to utilize our biomarkers in conjunction with clinical trials pursuing FDA approval for needed treatments.

Product & Business Model

The Next Generation of Technology Disrupting the Food Allergy Market

Individuals, caregivers, allergists, food manufacturers, therapeutic developers, and regulators are all looking for more detailed information on food allergy characterization to improve the safety of food-related decisions, increase access to accurate testing, and develop treatments for the growing number of food allergy individuals.

Individuals, caregivers, and allergists look to new tests to provide tolerance levels and reaction types, as existing food allergy testing such as IgE, component, and skin prick tests, do not identify these ranges. The current most accurate test in the market is the Oral Food Challenge, in which individuals consume the allergen in a clinical setting. This test can cause tremendous anxiety due to the potential risk of severe reactions such as anaphylaxis, and can take many months to schedule.  

Individuals and caregivers can access Allergenis testing, which has up to 93% accuracy, through their current allergist or our consumer-directed digital food allergy clinic launched in partnership with LifeMD. Allergists can order testing directly through our online portal.

Allergenis collaborates with therapeutic companies pursuing regulatory approvals in the field of food allergies, integrating our biomarkers into the development and clinical use of their products to advance the acceptance of reliable biomarkers as safe and effective alternatives to oral food challenges.

This partnership is mutually beneficial, as it increases trial enrollment and accelerates time-to-market for treatment solutions while generating profitable revenue for Allergenis. We provide our proprietary epitope mapping platform technology to therapeutic companies and partner with them to use our biomarkers for clinical patient selection and to evaluate the effectiveness of their therapeutic products. Our tests may also be used to track treatment response once products become FDA-approved and available, further securing our position as a global leader in this burgeoning therapeutic field, while generating additional revenue.

By diversifying our revenue streams, we create a sustainable business model and maintain a competitive advantage in the field of food allergy diagnostics and treatments. We are committed to driving innovation and progress in this field and look forward to continued growth and success through our collaborations with partners.

The Product

Allergenis utilizes an individual’s blood sample to conduct the diagnostic test. We receive the request from an allergist or from an online telehealth partner, coordinate the blood draw, and then provide the results along with a comprehensive, personalized guide to the individual and their allergist. 

While tolerance levels and subsequent reactions vary among individuals, existing food allergy testing does not identify these ranges. Current blood-test options in the marketplace produce ambiguous and inaccurate results which lack a full spectrum view of an individual’s allergy. The most commonly administered blood tests have as high as a 60% false-positive rate, while the gold standard tool, an oral food challenge (OFC) is costly, time-consuming, and sometimes anxiety-inducing due to the potential risk of clinical reaction. The Allergenis Peanut Diagnostic test is 93% accurate compare to OFC and can be used as an alternative.

The Allergenis test works by a proprietary method of analyzing epitopes, or the exact location where the IgE antibody binds to the cell, and is thus recognized by the immune system. By focusing on antibody binding to immunodominant epitopes versus the whole antibody (IgE), Allergenis can better determine which epitopes catalyze reactions and can predict an individual’s likelihood of having a serious reaction from a food allergen with up to 93% accuracy. We have been issued proprietary insurance billing codes and have established reimbursement rates on the federal clinical lab fee schedule to make our commercial tests accessible to individuals everywhere. 

*The above testimonials may not be representative of the opinions or the experiences of other customers and is not a guarantee of future performance or success.

*The above testimonial may not be representative of the opinions or the experiences of other customers and is not a guarantee of future performance or success.

The Market & our traction

Validated Technology Filling A Major Market Need

According to research by the Food Allergy Patient and Family Registry, 32 million Americans suffer from food allergies, including 1 in 13 children. While the proprietary AllerGenis test may address most of this market, in the near term AllergGenis is focused on the top three food allergens, peanut, milk and egg, which impact 3.5 million children and a large cross-section of adults.

Given food allergies often evolve over time (i.e., sometimes they are outgrown) combined with a growing level of various immunotherapies, periodic retesting by customers is expected. Therefore, not only is AllerGenis addressing a large market in terms of likely testing events, those individuals will also most likely use our test multiple times, creating repeat sales. Even if Allergenis achieves only a 1.0% penetration of its three initial markets (peanut, milk, and egg testing) for children and adults, there is a sizable target addressable market and revenue opportunity.

In 2022, we raised over $4 million in follow-on funding, bringing our total raised to $19 million. In the same year, we validated and launched our peanut reactivity threshold assay. Our technology has been validated by multiple peer-reviewed studies, including the Jaffe Food Allergy Institute at Mount Sinai, and the Sean Parker Institute for Food Allergy at Stanford University. We routinely present at premiere allergy conferences including AAAA&I, ACAAI, EAACI, the Gordon Conference, and the Next-Generation Food Allergy Drug Development Summit. We have on-boarded over 200 allergists at academic centers and clinics throughout the U.S., and partnered with multiple therapeutic companies enabling the use of biomarkers in clinical trials focused on bringing FDA-approved therapeutic interventions to better treat and manage food allergies.

*The above testimonial may not be representative of the opinions or experiences of other publications and is not a guarantee of future performance or success.

WHy Invest

Changing the Way We Understand Food Allergies

While Allergenis technology benefits the individual, it inherently may also benefit:

  • Medical ProvidersImproving outcomes through personalized care, generating higher revenue from increased procedures, and administration of therapy.
  • Employers, Commercial and GovernmentImproved employee/members' satisfaction, better outcomes, more efficiency, and parents are less likely to have to decide whether to work or stay home to monitor their child(ren)'s diet.
  • Therapeutic DevelopersIncreased trial enrollment and accelerates time-to-market for treatment solutions.
  • Food & IndustryIncreased clarity allows for more consumption of food products.
  • Travel & HospitalityIncreased clarity allowed reduced travel anxiety and higher utilization of services.

We believe Allergenis is the first in the food allergy market to offer precision molecular diagnostics with a machine-learning, AI-enabled approach to predictive analytics. Additionally, Allergenis is the first food allergy test that can be initiated by a caregiver and/or individual via a partner telemedicine channel, all while receiving the necessary medical support from an allergist with expertise in managing food allergies.

Our testing platform has been validated and proven to have an up to 93% accuracy rate compared with OFC, with numerous patents issued on an array of products. We are now ready to ramp up commercial activity by adding sales and marketing staff, increasing market share, and creating widespread adoption of our in-market Allergenis Peanut Diagnostic.

With key immunodominant epitopes identified for other allergens, this raise will also fuel the final validation and 2023 commercial launch of a suite of assays for milk allergy and accelerate the development of highly demanded allergens including egg, wheat, and tree nuts. Join us as we harness the potential of our technology to help change the lives of people living with food allergies. 


10 East 40th Street, Suite 3210
New York, NY 10016

Allergenis provides the next generation of food allergy testing using cutting-edge systems biology and data analytics to accurately determine allergic status, tolerance levels, and reaction severity for a more informed quality of life when living with a diagnosis of food allergy. Additionally, Allergenis is the first food allergy test that can be initiated by a caregiver and/or individual via a partner telemedicine channel, all while receiving the necessary medical support from an allergist with expertise in managing food allergies. We currently provide peanut allergic status and threshold testing in 49 states, and Washington DC, with milk allergy testing launching later this year, and egg allergy testing in 2024.


James A. Garner
James A. Garner
Chief Executive Officer
Jim has more than 33 years leadership experience providing products and services to help families and doctors better diagnose and manage health conditions. Expertise in developing and commercializing products and services for life sciences commercializing, distributing, and licensing more than 40 diagnostic products and services. Central in four mergers & acquisitions and raising $100M in venture capital and private equity funding. 

Jim was the Chief Business Officer of Integrated Diagnostics, a diagnostics company developing technology for early detection, prediction and prevention of disease. Prior to that he was Senior Vice President of Global Sales and Senior Director of Corporate Development for UnitedHealth Group, Director of Marketing & Corporate Development at Elan Diagnostics and Sales Manager at DIANON Systems.

Jim received the Meritorious Service Medal among other honors while serving as Captain in the United States Army where he was Air-Cavalry Troop Commander, Aviation Task Force Operations Officer, Attack and Scout Helicopter Pilot, among other roles and distinctions.

Jim lives in Florida with his family where he enjoys surfing, golfing and tennis with his wife and two sons.

Albert A. Luderer, Ph.D.

Albert A. Luderer, Ph.D.

Chairman of the Board

Al has more than 40 years of successful leadership in medical diagnostics, laboratory medicine and therapeutic development. Dr. Luderer is currently CEO and cofounder of Indi Molecular, a synthetic biology company which was a 2013 spinoff of Integrated Diagnostics where he was the founding CEO. Integrated Diagnostics discovered and commercialized the first non-invasive cancer rule out molecular diagnostic for early stage non-small cell lung carcinoma. Biodesix (BDSX) acquired Integrated Diagnostics in 2018. Earlier in his career, Luderer served as CEO of BioTrove Inc., a Molecular Biological Tools company acquired by Life Technologies in December 2009. Dr. Luderer’s prior positions include: CEO of Therapeutics company Light Sciences Inc.; President of bioMérieux, Inc. (BIM.PA); Vice President of Technology and Business Development for Dianon Systems (now Lab Corp); Vice President of Technology Development and Support at Boehringer Mannheim (Now Roche) and; Head of Biomedical Research for Corning.

Dr. Luderer has developed and commercialized major In Vitro Diagnostic (IVD) systems including the global market leader for microbial detection and antibiotic susceptibility testing – Vitek®II; co-invented and established Standard of Care Diagnostics in cancer detection and has participated in the creation of one of the dominant global IVD companies – Siemens Diagnostics – through his participation in the negotiation and formation of the joint venture IVD firm Ciba Corning. Dr. Luderer holds a Ph.D. from Rutgers University where he was an NSF predoctoral fellow and performed postgraduate work in immunology and genetics at Sidney Kimmel Medical College (formerly Jefferson Medical College). He is an independent director of BioNano Genomics (BNGO) and the chairman of Allergenis.

Hugh A. Sampson, M.D.

Hugh A. Sampson, M.D.

Board Member

Hugh is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine in New York and has over 40 years’ experience in clinical and basic research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders. His research has been funded continuously by grants from the NIH, including the Principal Investigator for the Consortium for Food Allergy Research, has authored/co-authored over 550 original articles and 90 book chapters primarily on various aspects of food allergic disorders, and has chaired working groups that produced standardized criteria for diagnosing anaphylaxis and conducting double-blind placebo-controlled oral food challenges (Practall Guidelines).
Russ S. Fein

Russ S. Fein

CFO & Board Member

Russ began his career in 1987 in the Mergers and Acquisitions department of Jefferies & Company, Inc. and then spent a number of years in the merchant banking field where he negotiated acquisitions and investments both as principal and agent and often stepped in as COO and/or CFO of portfolio companies, leading growth strategies and building professional organizations around entrepreneurial businesses. In 1995, he left the investment banking field to work full time in senior management roles at a number of small and large operating businesses, including a chain of martial art studios, an Internet incubator and most recently as the Vice President, Worldwide Business Operations for Westcon Group, a $4 billion distributor of communications and technology equipment, where he also held the role of General Manager for a $300mm U.S. division. Russ received his MBA from the University of Chicago Graduate School of Business and graduated from Union College with honors in Managerial Economics.
David A. Esposito

David A. Esposito

Board Member

David is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers.

David is currently the CEO of ONL Therapeutics based in Ann Arbor, MI. ONL Therapeutics is developing therapeutics based on Fas inhibition to protect the vision of patients with retinal disease. David is the former CEO of Armune BioScience. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.

He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division. David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.

Vijay Aggarwal, Ph.D.

Vijay Aggarwal, Ph.D.

Board Member

Vijay brings extensive leadership in clinical diagnostic services as well as institutional and individual investment experience to Allergenis. As Managing Partner of The Channel Group, Dr. Aggarwal provides capital formation services to healthcare companies. He is also an active angel investor. Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a predictive pathology company. From 2001 to 2004, he served as President of AAI Development Services, Inc., a global contract research organization. Following the acquisition of SmithKline Beecham Clinical Laboratories (SBCL) by Quest Diagnostics, Dr. Aggarwal served on the Chairman’s Council and served as President of Quest Diagnostic Ventures.

During his tenure with SBCL, he held many positions, including Executive Vice President of Laboratories, having direct responsibility for all of SBCL’s U.S.-based laboratories, and as Vice President of Managed Care, responsible for third party reimbursement.

In addition to his position with Allergenis, he holds Board positions at Accugenomics, Interpace Biosciences, Moleculera and Slone Partners. He holds a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia.

John C. Simons

John C. Simons

Board Member

John has spent over 36 years as a banker to small and mid-size businesses and the families that own them. John was an Executive Vice President for Bank of America (formerly Fleet National Bank) in the Regional Commercial Services Group, responsible for small business, middle market and corporate banking in New York City, Long Island, New Jersey and the Hudson Valley area. He was also Market Executive for FleetBoston Financial's activities in New York City. Prior to joining Fleet, John was a Senior Vice President with Chase Manhattan Bank. He began his career with Chemical Bank in 1983.

John is the Chairman of the Board of The United Hospital Fund, and a former director of amfAR, The American Foundation for Aids Research, The Greater Jamaica Capital Corporation and a former Trustee of the Brooklyn Academy of Music. John was also Chairman of the Lincoln Center Business Council and a member of Lincoln Center Corporate Fund. John was appointed by Mayor Bloomberg in 2003 to be a member of the Mayor's Fund to Advance New York City. John has a bachelor's degree from Trinity College.

Kristy Consalvo, MBA

Kristy Consalvo, MBA

Head of Marketing

Kristy is commercial leader with more than 16 years of experience within the diagnostics, medical device and laboratory services industries. She has consulted or worked with CareDx, Becton Dickinson (BD), Aspire Women’s Health, Boston Heart Diagnostics and Pion Inc. In her prior role as Senior Marketing Manager at Boston Heart Diagnostics, she launched a direct-to-consumer line of genetic testing, driving all aspects of the business from P&L management with project revenues of $3M, to the cross-functional implementation and management of operations, marketing, finance and customer care. 

Kristy’s expertise includes commercial strategy, building efficient organizations, marketing automation, product management, medical marketing, B2B and B2C business development, and genomics. She has a track record of launching novel technologies that change clinical practice both nationally and globally. With her undergraduate in Mechanical Engineering, she is skilled at taking complex, technical concepts and communicating them in a manner that is easily understandable.

Kristy is also a mother of four kids, 3 of which have or had food allergies (some have outgrown). She is intimately familiar with the pain and anxiety of food avoidance, the time and resources required for risk preparation, and the inadequacy of current food allergy testing that families must go through.   

Paul Kearney, Ph.D.

Paul Kearney, Ph.D.

Head of Product and Clinical Development

Paul brings decades of expertise in bioinformatics in which he has used world-class data science and machine learning to develop and commercialize multiple products (lung cancer, pregnancy, food allergy, CNS, and data science technologies).

Paul has developed five complex diagnostic products currently in clinical use including PreTRM from Sera Prognostics where he currently oversees the evidence development strategy and is the Chief Data Officer. Formally, he co-founded four successful biotech companies including Data Incites and Integrated Diagnostics which was acquired by Biodesix (BDSX) in 2018. 

Paul has developed multiple high-value diagnostics in oncology, pregnancy and food allergy with supporting evidence development of over 100 publications and 12 patents issued. He has also been successful and central in raising $200M in public and private funding and has experience assembling top management team of scientists, data analysts, laboratorians and IP experts to support company formation.

Thomas Vollmers

Thomas Vollmers

Head of Strategic Partnerships & Commercial Strategy

Thomas is an experienced Sales and Marketing Executive in the Pharmaceutical and Biotechnology Industry, specializing in Precision Medicine and Companion Diagnostics (CDx). He boasts extensive experience in US and Global CDx Commercialization across various therapeutic areas, including HIV, oncology, and allergic disease, and has successfully launched a wide range of therapeutic and diagnostic products.

As a dedicated professional, Thomas excels at forging strategic and long-term partnerships with stakeholders within the Therapeutic and CDx ecosystem. His deep understanding of diagnostic platforms, technologies, and trends, coupled with his ability to collaborate effectively with diagnostic manufacturers, reference labs, lab networks, and key opinion leaders (KOLs), positions him as a valuable contributor to the growth and success of healthcare companies.

Throughout his distinguished career, Thomas has held significant roles at renowned companies such as The Upjohn Company, GlaxoSmithKline, ViiV Healthcare, Pfizer, and Merck. In these roles, he has been pivotal in developing, implementing, and managing commercial strategies that propel growth and innovation in the therapeutic and diagnostic sectors.


Aug. 22, 2023 at 6:59 AM UTC
$10k - $1.24M
Non-Voting Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*The Offering Maximum Non-Voting Common Stock subject to adjustment for bonus shares. See “Investment Incentives and Bonuses.”

Voting Rights of Securities Sold in this Offering

Pursuant to the Subscription Agreement, investors agree to appoint the CEO, or his or her successor, as the investor’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with the Subscription Agreement and on behalf of the investor, (i) vote all Securities held of record by the investor (including any shares of the Company’s capital stock that the investor may acquire in the future), (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument at its own discretion, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the investor are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the investor is an individual, will survive the death, incompetency and disability of the investor and, so long as the investor is an entity, will survive the merger or reorganization of the investor or any other entity holding the Securities. Such proxy shall be binding upon the heirs, estate, executors, personal representatives, successors and assigns of the investor (including any transferee of any Securities held by investor); any transferee receiving the investor’s Securities (or any portion thereof) shall agree to be bound by the proxy as set forth in the Subscription Agreement. However, the proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale of common stock or the effectiveness of a registration statement under the Securities Exchange Act covering the common stock.

Investment Incentives and Bonuses1


Friends and Family

Invest within 72 hours and receive 10% bonus shares and a Food Allergy Care Kit.

Early Bird Bonus 

Invest within two weeks and receive 5% bonus shares.

Comb/Avid Investor

Invest $10,000+ within the first 48 hours and receive 20% bonus shares.


Tier 1 | Premier

Invest $1,000+ and receive a Food Allergy Care Kit.

Tier 2 | Silver

Invest $2,000+ and receive a Rebate Coupon* and a Food Allergy Care Kit.

Tier 3 | Gold

Invest $10,000+ and receive a Rebate Coupon, a Food Allergy Care Kit, 30-minute Zoom with CEO, Scientific & Medical Advisory Webinar, and 5% bonus shares.

Tier 4 | Diamond

Invest $25,000+ and receive a Rebate Coupon, Allergy Care Kit, 30-minute Zoom with CEO, Scientific & Medical Advisory Webinar, and 10% bonus shares.

Tier 5 | Platinum

Invest $100,000 + and receive a Rebate Coupon, a Food Allergy Care Kit, 30-minute Zoom with CEO, Advisory Webinar, and 15% bonus shares.

*Rebate Coupon valid for one Allergenis commercially available test (one food allergen) for one year from issue date and is fully transferable. Individual utilizing coupon must be eligible for testing.

The Allergy Care Kit is valued at approximately $60. Components may include but not guaranteed: water bottle, snack safe stickers, sample allergy guide, restaurant cards, red sneakers for Oakley keychain, food allergy book, and others.

30 Minute Zoom includes a 1:1 session with Allergenis CEO, Jim Garner.

The Scientific & Medical Advisory Webinar includes a 60-minute session with a member of our medical and/or development team.

1 In order to receive incentives and bonuses from an investment, you must submit a single investment in the same offering that meets the minimum incentive or bonus requirement. Bonus shares from perks will not be granted if you submit multiple investments that, when combined, meet the incentive or bonus requirement. All incentives and bonuses will occur when the Offering is completed.

The 10% StartEngine Owners' Bonus

AllerGenis will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Non-Voting Common Stock at $5.00/ share, you will receive 110 shares of Non-Voting Common Stock, meaning you'll own 110 shares for $5. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the aforementioned bonus.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.


Article Image
Yahoo Finance

Allergenis, Inc. Seeks Funding for Its Food Allergy Testing Technology for Accurate Allergic Status and Tolerance Levels

Article Image
Austin American Statesman

New test can show just how allergic your kids might be to peanuts

Article Image
Allergic Living

Epitope Mapping Test Diagnoses Peanut Allergy With Over 90% Accuracy

Article Image
Allergic Living

Test Shows: How Much Peanut an Allergic Child Can Tolerate

Article Image

Worried about mental health? You’re not alone.



Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into AllerGenis.


Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Owners bonus

Owner’s Bonus

Owner’s Bonus Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).



Nathaniel Putnam

5 months ago

Stories sell.. Post more from kids and parents about the benefits and ease of Allergenis tests compared to horrors of in-office testing.



Virginia Luke

5 months ago

How is this diagnostic test different from the ones already available on the market that measure IgA or IgE and include tolerance ranges at a cost under $300?



Ranajit Banerjee

7 months ago

On your website, it mentions that the price for the Allergenis peanut diagnostic test is $1,450.00. Is this the average price paid by customers or is typically negotiated down? With commercially available allergy tests costing only a fraction of this, how is Allergenis providing value? As you achieve scale, is there any effort to lower the price in the next few years?



Anthony Tarkowski

7 months ago

How many shares does the company intend on selling, and how many are already owned by someone? I want to be sure the value that I am paying is relevant. I am talking about total shares in the company not just what is on StartEngine.



Edgar Garcia

7 months ago

Hello, just curious if your forthcoming milk allergy test will also detect lactose intolerance? Thank you!



Adam Forster

7 months ago

Hello! Is the intention for Allergenis to sell large numbers of allergy tests or test kits or to earn consulting revenue and/or royalties working with pharma companies? Are these revenue streams each large enough to justify an investment here or is the pharma consulting work useful to fund the company as more allergy tests are developed? Also, can you provide a scale of the total market for food allergy tests that Allergenis is targeting?



Michael Stanis

7 months ago

Can you explain to me why revenue decreased by around 70% from 2021 to 2022 to a mere $74,140? I find that concerning given the valuation of $40 Million with 1.7 million having been spent on "Sales and Marketing" what kind of marketing have you been wasting millions of dollars on with a net revenue of $75,000 in an entire year? Also, considering your burn rate of around $300,000 /month you are on track to have no cash and be in significant debt in May. I would appreciate some insight into what your business is fundamentally valued on and how you plan to make real money, much less become profitable.



Wendy Van Peenan

7 months ago

Is it possible to invest through a trust?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!


With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA / SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.